Agios and Alnylam sign agreement for siRNA candidate
Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).
Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.